Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma

Table 2

Ocular MMP-9 status by study group.

	Preservative-free treatment (tafluprost) ()	BAK-containing treatment (latanoprost) ()	Untreated (control) ()
MMP-9 (>40 ng/mL)
Negative	25 eyes (83.3%)	16 eyes (53.3%)	25 eyes (83.3%)
Positive	5 eyes (16.7%^,‡)	14 eyes (46.7%)	5 eyes (16.7%^,‡)

Level of significance: p < 0.05; ^‡significance of difference relative to the BAK-containing treatment (latanoprost) group.